Thalidomide

4:41
COVID-19 in Germany
Katja Weisel
3:36
TOURMALINE-AL1: ixazomib for AL amyloidosis
Angela Dispenzieri
5:18
Immunomodulation for improving long-term outcomes in myeloma
Michel Delforge
4:23
AGMT_MM-1: the oral microbiome as a predictor of PFS in R/R myeloma
Heinz Ludwig
3:24
KRd vs KTd followed by K maintenance or control for high-risk myeloma
Heinz Ludwig
4:00
Positive learnings in myeloma management to come out of COVID-19 pandemic
Mohamad Mohty
4:36
Update on auto-SCT for myeloma
Mohamad Mohty
4:18
Novel drugs in the R/R MM: IMiDs
Enrique Ocio
2:20
Ultra high-risk myeloma
Graham Jackson
5:02
Drug resistance in multiple myeloma
Keith Stewart
2:54
Iberdomide plus dex effective and well tolerated in R/R MM
Niels van de Donk
2:56
Myeloma XI long-term follow-up: Graham Jackson update
Graham Jackson
10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al.
5:47
Toxicities of MM drug treatments
Ravi Vij
10:42
Highlights from IMW 2019 Part I
Francesca Gay et al.
2:21
MM: BTD plus a monoclonal antibody
Amrita Krishnan
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals